episodes in outpatient departments or within 48 hours of hospitalization between March and April 2016 in two community hospitals in Gyeonggi-do province, Korea (742 beds, Goyang-si; 132 beds, Yongin-si). Healthcare-acquired E. coli isolates that were collected after 48 hours of admission were excluded. The study was approved by institutional review boards as required by local hospital policy (NHIMC 2016-02-006).
Definitions
Sites of acquisition (community-associated or healthcareassociated) were determined as described by Friedman with some modifications. 7, 8 Healthcare-associated infections have any of following histories: attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the 30 days before the infection; hospitalized in an acute care hospital for 2 or more days in the 90 days before the infection. Others were defined as community-associated infection. The diagnosis of infection was made based on clinical, bacteriological, and radiological investigations. 9 
Microbiological analysis
Identification and susceptibility testing were performed using the Vitek 2 automated analyzer system (bioMé rieux, Marcy l'E'toile, France) with a VITEK AST2 N212 card (bioMé rieux). Antibiotic susceptibility was interpreted using CLSI criteria. 10 ESBL genotype was determined by PCR and sequencing. 11 For the detection of ST131, all isolates were screened by PCR for O16-ST131 and O25-ST131. 5 FimH type and H30Rx were determined by PCR and sequencing. 4, 12 2.4. Statistical analysis SAS software, version 9.2 was used for the statistical analysis (SAS Institute, Cary, NC, USA). Comparisons of proportions were tested using the Chi-square test or Fisher's exact test with the level of significance set as P value < 0.05.
Results
A total of 213 community-onset isolates were identified, consisting of 94 (44.1%) healthcare-associated (HA) isolates and 119 (55.9%) community-associated (CA) isolates, the majority of which were from urinary tract infections. No statistically significant difference was found in either infection or colonization status of CA isolates, compared to that of HA isolates (P = 0.701, Table 1 ). Although urinary tract infection was the most common type in both groups, bacteremia was more frequently encountered in the HA group than in the CA group and the two groups were different in the type of infection (P < 0.0001, Table 1 ). A total of 55 E. coli isolates (25.8%, 55/213) had ESBL genes, which were mainly CTX-M types such as CTX-M-15 and CTX-M-14. In addition, there was no statistically significant difference in ESBL genotypes between the CA and HA groups (P = 0.8752, Table 1 ).
Among CA isolates, 26.9% (32/119) were caused by the globally epidemic ST131 strain, which was similar to that of HA isolates (27.7%, 26/94) and there was no statistically significant difference in the proportion of globally epidemic ST131 clone or O25, O16, H30, or H30Rx subclones between CA and HA isolates (Table 1) .
According to ST131 subclones, ESBL positive rates and types were different (Table 2) . ST131-O25H30Rx subclones most commonly produced ESBLs, all of which were CTX-M-15 types, Table 1 Types of infections, extended-spectrum b-lactamase (ESBL) types, and the prevalence of sequence type 131 (ST131) of community-onset healthcare-associated (HA) and community-associated (CA) Escherichia coli episodes (N = 213) a Narrow-spectrum b-Lactamase. whereas only 29.4% of ST131-O16 subclones produced ESBLs, all of which were CTX-14 types. Antimicrobial resistance patterns showed distinct characteristics according to ST131 subclone, and in particular the H30Rx group showed prominent resistance to fluoroquinolones such as all resistant to ciprofloxacin or levofloxacin and 88% resistance to cefotaxime due to CTX-M type ESBL production (Table 3) . However, the antimicrobial resistance rates were similar in the HA and CA groups (Table 3 ).
Discussion
It is well known that the majority of community-onset E. coli isolates come from urinary tract infections, 13 and our study also showed that urinary tract infection was the most common type. Recently, the emergence of community-onset bacteremia via ESBLproducing E. coli has become a major concern. 8, 14 In this study, community-onset bacteremia was more frequently encountered in the HA group (possibly not as healthy as the CA group), suggesting that not only microbiological factors but also the impact of host factors are important for severe types of infections such as bacteremia.
Extended-spectrum b-lactamase (ESBL)-producing E. coli has become widespread in hospitals around the world since the late 1980s, 15 but a sudden worldwide increase in the mid 2000s is mainly due to sequence type (ST) 131 with resistance to quinolone and 3rd generation cephalosporin, which was suggested as the main cause of the spread of ESBL producing E. coli in the community. 3, 16 Not only community-onset E. coli infection but also asymptomatic carriage among health individuals without prior exposure to antibiotics increased. 17 Our study showed a high prevalence of ESBLs, mainly CTX-M, among community-onset E. coli isolates in Korean community hospitals. In the Asia-Pacific region, higher rates of ESBL-producing E. coli were observed in countries like China, India and Thailand, compared to Korea. 18 The incidence of notorious epidemic resistant clones of E. coli varies over time and geographic regions, and the ST131 E. coli clonal group has been evolving through the acquisition of new mobile elements. 19 Continuous monitoring of major epidemic resistance clones is needed for updated information regarding the status of ST 131 E. coli. In the most recent molecular epidemiology data of ST131 E. coli in Korea, the ST131 clonal group comprised 21% (57/268) of all E. coli isolates, 37% (21/57) of which were H30Rx subclones. 20 This study included both healthcare-onset and community-onset E. coli isolates, collected from urine or blood cultures between September 2012 and January 2013. Although direct comparisons are inadequate, considering different acquisition sites (our study includes only E. coli isolates from the community), our study showed that 27% (58/213) of E. coli isolates from the community belonged to the globally epidemic ST131 strain, 28% (16/58) of which were H30Rx subclones. Therefore ST131 E. coli infections in the community are already considerable in Korea, and ST131-O25H30Rx subclones could be considered potential driving factors, with their high ESBL (mainly CTX-M type) production rates as well as successful traits related to extensive virulence gene content and ongoing transmission.
2
Recently multiple sources of ST131 E. coli in the community have been suspected, including livestock, companion animals, sewage, waste water, and recreational waterways. 21, 22 This 'One Health' concept, which recognizes that the health of humans is connected to the health of animals and the environment, may be useful for promoting cross-sectorial collaborations and represents a possible solution for preventing the spread of multidrug resistance in the community. Nevertheless, it is important to emphasize that ST131 E. coli accounts for a large proportion of HA infections. 23 In our study, 44.1% (94/213) of patients had HA factors such as recent visits to a healthcare facility. Thus, It is reasonable to assume that the burden of ESBL producing E. coli in the community is affected by healthcare facilities (and vice versa) in a 'revolving door' pattern, 24 similar to that of CA methicillin-resistant Staphylococcus aureus.
25
In this study, considerable community-onset acquisitions of ST131 E. coli from two community hospitals were observed, and about half of them had history related to healthcare facilities, indicating the spread of multidrug-resistant E. coli to the community via healthcare facilities. Table 3 Antimicrobial resistance rate (%) of Escherichia coli isolated from two community hospitals 70  68  83  94  65  79  65  Piperacillin  69  64  80  88  65  78  62  Ampicillin/sulbactam  33  25  40  44  29  35  27  Cefoxitin  4  2  3  6  0  3  3  Cefotaxime  30  27  60  88  29  50  20  Ceftazidime  30  24  57  81  24  47  19  Meropenem  0  0  0  0  0  0  0  Imipenem  0  0  0  0  0  0  0  Ciprofloxacin  39  44  100  100  18  67  32  Gentamicin  23  25  51  56  35  43  17  Tobramycin  13  11  31  38  24  28  6  Amikacin  0  0  0  0  0  0  0  Cotrimoxazole  33  25  49  44  41  45  23 HA, community-onset healthcare-associated; CA, community-associated; all ST131 include O25-H30, O25-nonH30, and O16. a One isolate was excluded from the antimicrobial susceptibility test.
